Report topline data from the ASLAN004 multiple ascending dose trial in atopic dermatitis
Delivered after the deadline (89 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- 27 Sep 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We expect to report topline data from this trial in mid-2021.”
What we found
Evidence strength A What the grades mean
The company announced positive topline data from the ASLAN004 Phase 1 MAD study on 27 September 2021, after the mid-2021 deadline.
-
A ASLAN Pharmaceuticals Ltd 6-K filed 2021-09-27
“today announced positive topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD).” ✓ confirmed on the page
-
A ASLAN Pharmaceuticals Ltd 20-F filed 2022-03-25
“In September 2021, we announced topline data from our Phase 1 multiple ascending dose (MAD) study, conclusively establishing proof of concept for eblasakimab in AD” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Topline data from ASLAN004 MAD trial in atopic dermatitis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ASLAN Pharmaceuticals Ltd? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C722926-024838 · Corrections policy